Inhibitors of Bruton's tyrosine kinase (BTK) possess much promise for the treatment of oncologic and autoimmune indications. However, our current knowledge of the role of BTK in immune competence has been gathered in the context of genetic inactivation of btk in both mice and man. Using the novel BTK inhibitor PF-303, we model the clinical phenotype of BTK inhibition by systematically examining the impact of PF-303 on the mature immune system in mice. We implicate BTK in tonic BCR signaling, demonstrate dependence of the T3 B cell subset and IgM surface expression on BTK activity, and find that B1 cells survive and function independently of BTK. Although BTK inhibition does not impact humoral memory survival, Ag-driven clonal expansion of memory B cells and Ab-secreting cell generation are inhibited. These data define the role of BTK in the mature immune system and mechanistically predict the clinical phenotype of chronic BTK inhibition. The Journal of Immunology, 2014, 193: 000-000.
B
cell receptor-mediated signaling processes serve as checkpoints permitting the continuation of B cell development along with the culling of cells into particular B cell subset fates; ultimately, and with the appropriate secondary stimuli, B cells are activated to differentiate further into effector, memory, and potentially regulatory populations (1, 2) . The role of BCR signals in B cell fate at numerous junctures in development predict that clinical pharmacologic inhibition of BCR signaling will impact various B cell parameters in both mouse models and in human patients.
Bruton's tyrosine kinase (BTK) is required for B cell development, survival, proliferation, and differentiation (3) (4) (5) (6) (7) . This has been demonstrated largely through studies from X-linked agammaglobulinemia (XLA) patients, xid mice, and btk-deficient mice (4, 5, (8) (9) (10) (11) . In a btk-null setting, profound B cell developmental defects occur. These result in peripheral B cells presenting at low frequencies and in an immature state and containing a perturbed BCR repertoire; in addition, the B1 cell lineage is absent (4, 5, 12, 13) . In particular, XLA patients display a profound defect in B cell development and peripheral B cell accumulation, leading to severely impaired humoral immunity that is characterized by diminished serum Ig levels and abnormal splenic architecture (14) . Resulting from the near ablation of B cells in these patients and the consequential hypogammaglobulinemia, patients typically manifest with recurrent bacterial infections. The xid strain of mice develop a less dramatic phenotype than XLA patients as xid B cells cells can successfully develop into immature B cells. Defects are observed in xid mice in naive mature follicular (FO) B cell frequency, B1 cell development, and serum Ig levels (4, 5, (15) (16) (17) .
The obligate role of BTK in transmitting activating signals downstream of the BCR has generated much effort to pharmacologically target BTK in B cell-driven maladies. Indeed, in preclinical models, BTK inhibitors result in therapeutic efficacy in oncologic and autoimmune settings, including models of rheumatoid arthritis and systemic lupus erythematosus (SLE) (18) (19) (20) (21) (22) (23) (24) . In the clinic, promising results with the BTK inhibitor ibrutinib have been observed in relapsed chronic lymphocytic leukemia and relapsed or refractory mantle cell lymphoma (25, 26) . However, the role of BTK in B cell development and in generating and sustaining a fulminate humoral immune response has been defined largely in the absence of a functional btk gene, either through the use of xid-or btk-knockout mice (4, 5, (27) (28) (29) , or by characterizing B cells from, and the overall immune competence of, XLA patients (30) (31) (32) . A systematic study of how BTK inactivation in an otherwise wild-type setting impacts the mature immune system has not been performed.
Knowledge of how BTK inhibition impacts the wild-type B cell pool and humoral immune responses will predict the immune competence of patients undergoing long-term BTK inhibition and may predict, mechanistically, the B cell-driven maladies that are sensitive to BTK inhibition. In this study, the novel BTK inhibitor PF-303 was used to explore the impact of BTK inhibition in both acute and chronic settings on the mature immune system in mice.
Materials and Methods

Mice and immunizations
All procedures using animals were in accordance with regulations and established guidelines and were approved by the Pfizer Institutional Animal Care and Use Committee. CBA/CaJ, CBA/CaHN-Btk xid /J (xid), B6.SJL-Ptprc a Pepc b /BoyJ (CD45.1 + ) C57BL/6J, BALB/cJ, OT2 (B6. Cg-(TcraTcrb)425Cbn/J), and B1-8 hi (CBy.129P2(B6)-Igh , tm1Mnz . /J) mice were obtained from The Jackson Laboratory (Bar Harbor, ME); C57BL/6 RAG2 2/2 mice were obtained from Taconic (Hudson, NY). All mice were used between the ages of 8 and 12 wk. The following immunogens were used: NP-LPS (25 mg), NP 23 -CGG (25 mg), NP 3 -CGG (25 mg), and NP-Ficoll (100 mg) (all from Biosearch Technologies); PE (10 mg; Chromaprobe); alum (100 ml; Thermo Fisher Scientific), and ODN1826 (25 mg; InvivoGen). For in vivo B cell activation, 200 ml anti-IgD antisera (eBioscience) or 100 mg anti-CD40 (clone 1C10; BioLegend) was used. A total of 100 ml extensively washed SRBCs (Colorado Serum) was injected i.p. BrdU (Sigma) was added to the drinking water, at a concentration of 1 mg/mg, supplemented with 1% sucrose. All Ags and adjuvants were administered i.p. in a volume of 200 ml in sterile PBS.
Serology
Serum anti-NP and anti-PE IgM and IgG titers were assessed using a custom assay (Meso Scale Discover, Gaithersburg, MD), according to the manufacturer's recommendations. Blank plates (L15xB-3) were coated with NP 16 -BSA (Biosearch Technologies) or PE (Chromaprobe) overnight, blocked according to the instructions, serum diluted between 1:1,000 and 1:10,000 in the recommended Ab-dilution buffer, and added to plates in duplicate. Ab was detected using an anti-IgM or anti-IgG Sulfo-Link secondary and compared with a standard derived from hyperimmune serum raised against NP or PE. Serum BAFF levels were assessed using a commercially available murine BAFF ELISA (R&D Systems). Serum Ig titers were assessed using a multiplexed isotyping assay (Meso Scale Discover), according to the manufacturer's recommendations. To assess phosphorylcholine Ab titers, blank MSD plates were coated with PC 13 -BSA (Biosearch Technologies) overnight, blocked according to the instructions, and serum diluted 1:40 in the recommended Ab-dilution buffer. Ab was detected using an anti-IgM Sulfo-Link secondary.
ELISPOT
For detection of total IgM and IgG Ab-secreting cells (ASCs), ELISPOT plates were coated with unlabeled goat anti-mouse Ig (H+L) (SouthernBiotech) in PBS at 1 mg/ml and incubated overnight. Splenocytes were plated in RPMI 1640 containing 10% FCS and incubated for 4 h at 37˚C. Detection was performed with alkaline phosphatase-conjugated goat Abs specific for mouse IgM or IgG. Plates were developed and analyzed as above.
PF-303 formulation and selectivity assessment
In vitro studies were performed using crystalline compound dissolved in DMSO. In vivo studies were performed using PF-303 prepared in 0.05% methylcellulose 2% Tween in sterile water. Per os dosing by oral gavage was administered in a volume of 200 ml. Broad kinome profiling was performed to assess compound selectivity using in vitro enzyme assays conducted through Invitrogen or the University of Dundee (Dundee, Scotland, U.K.) and measured at Km (ATP) for the enzyme.
Quantitative RT-PCR and microarray analysis
For quantification of mRNA transcripts by quantitative RT-PCR (QRT-PCR) and microarray analysis, DNase-treated mRNA was purified using QIAGEN RNeasy columns, according to the manufacturer's instructions. Reactions were run on an Applied Biosystems ViiA 7 Real-Time PCR System using the qScript One-Step Fast qRT-PCR Kit, ROX (Quanta Biosciences). The following TaqMan QRT-PCR primers were used: Igh-6: F: 59-TCACAAGTGTTGCTGTCTCC-39, R: 59-CTGGGAGGGTTTGG-TTCTTAC-39, and Probe: 59-TGGTATGCAAAATCCACTACGGAGGC-39 and ActB: F: 59-ACGGCCAGGTCATCACTATTG-39, R: 59-CAAGAA-GGAAGGCTGGAAAAGA-39 and Probe: 59-CAACGAGCGGTTCCGAT-GCCC-39 (Integrated DNA Technologies). TaqMan probes employed to quantify mRNA levels include c-Myc: Mm00487803_m1; Bcl-xl: Mm00437783_m1; Ccl3: Mm00441258_m1; Egr1: Mm00656724_m1; CD98HC: Mm00500521_m1; Ebi2: Mm01234672_m1; Egr2: Mm00456650_m1; Irf4: Mm00516431_m1; Igh-5: Mm03979980_s1; and Cd19: Mm00515420_m1 (Applied Biosystems).
Transcriptional profiling
Total RNA from ex vivo-harvested B cells was purified using the RNeasy Mini Kit (QIAGEN), as per the manufacturer's protocols. Following the manufacturer's recommendations, 150 ng total RNA from each sample was used to prepare biotinylated cRNA for analysis on the Mouse Genome 430 2.0 expression arrays (Affymetrix). Sample generation, processing, labeling, and fragmenting were performed using the GeneChip 39 IVT Express Kit (Affymetrix). A GeneChip Hybridization, Wash, and Stain Kit was used for sample hybridization to the mouse arrays on a Fluidics Station 450 (both from Affymetrix). Finally, arrays were scanned using a GeneChip Scanner 3000 7G (Affymetrix) with autoloader, following the standard protocol. Gene expression profiling data were extracted using Affymetrix Microarray Suite 5.0 (MAS 5.0) software and used for subsequent statistical analyses. Analyses were performed using GeneData Expressionist. Only transcripts that were called as present in 80% of the samples and expressed at an average signal level . 20 signal units in any one group were used for further analysis. A total of 20,028 qualifiers met these criteria and were carried forward in the analysis. Data QC identified one strong outlier sample in the "PBS, vehicle" group that was subsequently removed from further analysis. All microarray data are available in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE56483.
Flow cytometry
Single-cell suspensions from spleens were generated using Miltenyi Biotec C-tubes by GentleMACS, as per the manufacturer's instructions. Singlecell suspensions from spleen were treated with RBC lysis buffer (Sigma) and washed with FACS buffer (PBS with 1% FCS). Cells were counted on a Guava ViaCount (Millipore). Cells were incubated with anti-CD16/32 (Fc block; clone 2.4G2; BD Pharmingen), washed, and stained with primary Abs diluted in FACS buffer for 30 min at 4˚C. Abs used in these studies included CD11b-PerCP Cy5.5, CD3-PerCP Cy5.5, B220-Alexa Fluor 700, CD38-Alexa Fluor 647, and CD45.1-allophycocyanin Cy7 (all from BioLegend); B220-V450, Gr1-PerCP Cy5.5, CD86-PE, IgD-V450, IgG1-FITC, CD23-PE Cy7, CD23-FITC, IgG1-FITC, and CD5-PE (all from BD Pharmingen); CD93-PE, B220-allophycocyanin Cy7, IgMallophycocyanin, IgM-eFluor 650, and CD21/35-allophycocyanin Cy7 (all from eBioscience); and PNA-FITC (Vector). PE was used to detect PEspecific B cells at a concentration of 0.5 mg/ml. BrdU incorporation was detected using an anti-BrdU-Alexa Fluor 488 Ab and intracellular stain protocol, according to the manufacturer's instructions (eBioscience). To detect BrdU incorporation of PE-specific memory B cells by FACS, splenocyte preps were depleted of IgD + cells using anti-IgD-biotin/ streptavidin magnetic beads and negative selection over a magnetized column (Miltenyi Biotec). OT2 T cells were stained with 5 mM CFSE (Sigma) for 10 min at 37˚C in RPMI 1640, quenched with RPMI 1640 + 5% FBS, and washed. Cells also were stained with LIVE/DEAD Fixable Aqua Dead Cell Stain (Invitrogen), per the manufacturer's instructions. Between 200,000 and 2,000,000 live events were counted using a Fortessa flow cytometer (Becton Dickinson) and analyzed used FlowJo software (TreeStar). All samples were gated first on "live" (Aqua LIVE/DEAD 2 ) singlets. In some experiments, assessment of WBC populations was quantified using a CELL-DYN (Abbott) prior to further analysis.
BAFFR-Fc
An expression construct for the soluble BAFFR-Fc was generated by fusing DNA sequences encoding an Ig signal peptide, the extracellular domain of BAFFR (aa 2-76), and a mutated Fc region from the mouse IgG2a H chain. An IgG2a mAb specific for Eimeria tenella was used as a negative control. The following mutations were included in the Fc domains to reduce binding to FcgRI and FcgRII and to reduce complement fixation: L235E, E318A, K320A, and K322A. Proteins were generated in CHO cells and purified by Protein A columns. Mice were injected with 100 mg i.p. daily in a volume of 200 ml.
Adoptive transfers
For T2/T3 adoptive transfers, a two-step purification method was used to purify T2 and T3 B cells. CD93 cells were enriched from the spleens of 20 C57BL/6J mice by staining with CD93-PE, followed by positive selection using anti-PE magnetic MicroBeads and MACS LS columns (both from Miltenyi Biotec), according to the manufacturer's instructions. T2 and T3 cells were sorted to purity on a FACS Aria II. Between 1 and 3 3 10 6 cells of each subset were obtained per sort. For B1 B cell adoptive transfers, peritoneal cavity contents from C57BL/6J mice were obtained by peritoneal lavage. Cells were washed with cold PBS/0.5% BSA/2 mM EDTA and transferred into RAG2 2/2 mice at a 1:1 donor/host ratio. In all adoptive-transfer experiments, cells were transferred i.v. in a volume of 200 ml ice-cold PBS. When recipient mice would be receiving PF-303 for the duration of the experiment, they were dosed with inhibitor by mouth 2 h prior to adoptive transfer of cells. For memory B cell adoptive transfers, spleens were harvested from BALB/c mice that were immunized 90 d prior with PE/alum and crushed into single-cell suspensions. CD138 + cells were depleted by incubating the cells with CD138-PE Ab (BD Pharmingen), followed by anti-PE MicroBeads (Miltenyi Biotec), and flowing the cells through a magnetic column. CD138 + cell frequency was reduced from 0.42 and 0.342% to 0.0657 and 0.0215% of total cells, respectively, in two experiments. The flow-through was adoptively transferred at 40-60 3 10 6 cells/host. Eighteen hours later, mice were dosed with either vehicle or 10 mg/kg PF-303 and challenged 2 h later with 10 mg PE in PBS. Serum Ab titers were assessed 96 h after challenge.
In vitro assays
For the IgM-internalization assay, B cells were purified by negative depletion (B Cell Isolation Kit; Miltenyi Biotec) and kept on ice. Cells were incubated with 10 mM PF-303 or fostamatinib for 30 min on ice, with inhibitor kept in solution for the duration of the experiment. Cells were incubated with 10 mg/ml goat anti-IgM Fab-biotin or F(ab9) 2 -biotin on ice. An aliquot of unlabeled cells was set aside as a negative control. B cells were plated at a density of 100,000 cells/well in a 96-well plate and suspended in media prewarmed to 37˚C. At the indicated time points, B cells were removed in triplicate at a volume of 100 ml and placed in a 96-well plate containing 100 ml 4% formaldehyde on ice. Subsequently, plates were washed five times with PBS, and IgM expression levels were detected using SA-FITC by FACS. Data are plotted as geometric mean fluorescent intensity (GMFI) relative to T = 0 GMFI. Where indicated, mice were pretreated for either 2 h or 5 d with 30 mg/ kg PF-303, quaque die dosing. For B cell/OT2 coculture experiments, B cells were incubated first with 10 mg/ml F(ab9) 2 -biotin (Jackson ImmunoResearch), washed in cold PBS, and incubated with the OVA Ag-delivery reagent (Miltenyi Biotec). ISQ peptide was added at a concentration of 10 mM where indicated. CFSE-stained OT2 cells (50,000) were added to OVA-targeted B cells (50,000) and incubated for 72 h in a round-bottom 96-well plate in a volume of 200 ml. 
Results
Impact of BTK inhibition on primary Ag-driven Ab responses
The compound (R)-5-amino-3-(4-(4-chlorophenoxy)phenyl)-1-(1-cyanopiperidin-3-yl)-1H-pyrazole-4-carboxamide (PF-303; structure shown in Fig. 1A and TEC was demonstrated; however, high selectivity was achieved for other members, including ITK and JAK3 (.10,000-fold selective). High kinome selectivity also was seen for the closely related Src family kinases, including LYN, SRC, and LCK (2000-7000-fold selective). Potency in inhibiting anti-IgM F(ab9) 2 -driven B cell proliferation in vitro was observed in mouse primary B cell assays with an IC 50 of 2 nM (data not shown). A short-term in vivo model in which naive B cells are activated by injection of agonistic anti-IgD was first used to assess the impact of PF-303 on BCR-mediated B cell activation. Of note, xid mice were reported to be hyporesponsive to this method of in vivo B cell activation (33) . In vivo treatment of mice with PF-303 2 h prior to anti-IgD injection prevents, in a dose-dependent manner, anti-IgDdriven CD86 induction by B cells, yet it does not impact CD40-mediated CD86 induction, as assessed by ex vivo analysis (Fig. 1B) (in vivo IC 50 = 201.5 nM; Fig. 1C ). The impact of PF-303 in Ags eliciting T-independent (TI) type I or type II or T-dependent (TD) Ab responses were assessed next. PF-303 prevents Ab responses to the TI type II Ag NP-Ficoll (Fig. 1D) but not responses to the TI type I Ag NP-LPS (Fig. 1E ) while minimally impacting responses to the TD Ags NP-CGG and PE (Fig. 1F, 1G ). These data are in agreement with studies using xid-and BTK-knockout mice (4, 29, 34, 35) . By using the V H B1-8 hi BCR-transgenic mouse (36), we assessed the impact of PF-303 on TD Ab responses elicited in response to either high-or low-affinity cognate BCR/Ag interactions. BTK inhibition mildly impacted responses driven by low-affinity interactions, whereas high-affinity responses were significantly reduced (Fig. 1H) . These data indicate that BTK inhibition effectively inhibits BCR-mediated B cell activation and responses to TI type II Ags and TD Ab responses driven by high-affinity Ag/BCR encounters.
Impact of PF-303 on the B cell transcriptome and implication of BTK in tonic BCR signaling
We next investigated the impact of PF-303 treatment on the in vivo B cell transcriptome. Mice were dosed with PF-303, injected with agonistic anti-IgD 2 h later, and B220 + CD23 + B cells were isolated and transcriptionally profiled after an additional 2 h (Fig. 2A) . Pharmacokinetic and pharmacodynamic modeling demonstrated that BTK was fully occupied by PF-303 for the duration of the experiment (data not shown). Principal component analysis of profiled B220 + CD23 + B cells indicated a substantial impact of PF-303 on both anti-IgD-treated and untreated groups (Fig. 2B) . ANOVA analysis of the four treatment groups identified 6495 transcripts that were modulated by anti-IgD treatment (p , 0.001); these transcripts were deemed BCR dependent. Of the BCR-dependent transcripts, K-Means clustering was used to identify four clusters (Fig. 2C) , with BTK-independent or -dependent transcripts additionally identified whose expression either increased or decreased during anti-IgD treatment. ANOVA analysis also identified 2463 BTK-dependent transcripts modulated by PF-303 treatment from the four treatment groups (p , 0.001). Demonstrating that BTK modulates BCR-driven signals in this setting, a large majority (78%) of BTK-dependent transcripts also were BCR dependent (Fig. 2D) . In quiescent B cells, PF-303 treatment modulated 537 transcripts (p , 0.01, Student t test) (Fig. 2E, 2F) ; of these transcripts, the majority (70%) also were BCR dependent (Fig. 2E) , indicating that PF-303 is modulating transcripts downstream of tonic BCR signals in quiescent B cells. Of the transcripts modulated by PF-303 in quiescent and anti-IgDactivated B cells, 231 transcripts were found to overlap (Fig. 2F) , with 43% of BTK-dependent transcripts in quiescent B cells similarly BTK dependent in the setting of acute anti-IgD-mediated BCR activation. Finally, targets previously demonstrated to be induced early after BCR signaling were examined by QRT-PCR analysis (Fig. 2G) (37, 38) , with anti-IgD-driven induction of c-Myc, Bcl-x L , CCL3, EGR1, CD98HC, EBI2, EGR2, and IRF4 transcripts determined to be dependent on BTK activity. Collectively, these data identify BTK-dependent transcripts downstream of acute and tonic BCR signals.
BTK inhibition suppresses cognate B cell-mediated activation of T cells and germinal center initiation and progression
The data presented thus far demonstrate that PF-303 inhibits BCR signaling and negatively impacts various Ag-driven Ab responses in vivo; however, TD Ab responses were only mildly perturbed. We next further examined the impact of BTK inhibition on TD immune responses. First, we observed that, in vitro, PF-303 and the SYK inhibitor fostamatinib did not impact the BCR internalization rate by B cells following acute BCR cross-linking by F(ab9) 2 fragments (Fig. 3A) . However, when OVA Ag was targeted to a F(ab9) 2 -cross-linked BCR and presented by B cells to cognate OT2 CD4 T cells, we observed that PF-303 suppressed OT2 T cell proliferation, as assessed by CFSE dye dilution (Fig. 3B) . This suppression could be largely overcome by the exogenous addition of the OVA 323-339 peptide. These data indicate that BTK is required for fulminate B cell-mediated cognate activation of CD4 T cells in vitro (Fig. 3B) .
The xid mouse, in response to TD Ags, forms a diminished, but not eliminated, intrafollicular germinal center (GC) reaction capable of somatic hypermutation and memory B cell generation (27) . In vivo, PF-303 led to a complete suppression of GC (defined as B220 + Dump 2 CD38 lo PNA + ) onset in mice immunized with SRBCs 7 d prior (Fig. 3C) . PF-303 also was capable of eliminating already-established SRBC-elicited GCs within 48 h of PF-303 treatment initiation (Fig. 3D) . (Fig. 3E) . Together, these data demonstrate that BTK inhibition suppresses cognate B cellmediated activation of CD4 T cells, prevents the generation of GCs, and drives the dissolution of established GCs.
Chronic BTK inhibition perturbs peripheral B cell subsets and abrogates the T3 B cell subset Given the paucity of mature B cells in xid and XLA hosts, we examined the impact of chronic PF-303 dosing on B cell subset frequencies. After 14 d of treatment with a dose of PF-303 providing full occupancy of BTK over the entire dosing period, B220 + B cells were decreased in the spleen and lymph nodes but not in the peripheral blood (Fig. 4A , lymph node data not depicted). Serum BAFF levels were increased in PF-303-treated cohorts (Fig. 4B) . Upon further dissection of the B220 + population, a significant decrease in number was observed in the mature naive FO and marginal zone B cell subsets (Fig. 4C, 4D) . The most dramatic impact of PF-303 was the dose-dependent ablation of the T3 B cell subset in all organs examined ( Fig. 4C-E) ; notably, the T3 B cell subset was the only subset modulated by PF-303 in the peripheral blood (Fig. 4E) . The kinetics of T3 B cell frequency in the peripheral blood were examined in a pulse-chase experiment, with T3 B cell abrogation detectable as early as 4 d after the initiation of dosing (Supplemental Fig. 1A) . Importantly, and indicating that a 14-d dosing period may be an appropriate length of time to assess the impact of chronic dosing of BTK inhibitors, longer dosing periods do not amplify changes observed upon chronic PF-303 dosing, including decreased T3 B cell frequency and total and FO B cell subset frequencies in the peripheral blood (Supplemental Fig. 1 ). These data show that chronic BTK inhibition reduces the total numbers of various B cell subsets in secondary lymphoid organs but not the peripheral blood, and it abrogates the presence of the T3 B cell subset. The abrogation of the T3 B cell subset is consistent with the absence of this subset in xid mice (39) . However, it is not known whether BTK is required for the development of the T3 B cell subset or for its survival and persistence. We next determined how BTK function impacts the T3 B cell subset. We FACS sorted and adoptively transferred CD45. (Fig. 5A) . When T2 B cells were transferred into PF-303-treated hosts, the cells were instead blocked from differentiating further into T3 B cells (7.5%) and preferentially remained T2 cells (10.7%) or differentiated into FO cells (64%) (Fig. 5B) . Strikingly, upon adoptive transfer of T3 cells, there was no difference in the differentiation profiles between either vehicle-or PF-303-treated hosts (Fig. 5C, 5D) . Importantly, and serving as an internal control, a reduction in the CD45.1 + host T3 B cell population was observed in both PF-303-dosed cohorts compared with vehicle treatment (Fig. 5C, 5D ). These data indicate that ablation of the T3 B cell subset by chronic dosing of PF-303 is the result of a developmental block imparted by BTK inhibition in the differentiation of T2 B cells into T3 B cells.
Chronic BTK inhibition leads to increased levels of surface IgM expression by B cells and reduced IgM internalization rates
In our chronic dosing studies, we observed that B cells from mice treated with PF-303 consistently displayed increased surface IgM expression levels compared with vehicle controls, with this increase occurring in a dose-dependent manner (Fig. 6A, 6B) . Interestingly, IgD and IgG1 surface expression levels were impacted either mildly or not at all (Fig. 6C, 6D) . Indeed, data collected across nine in vivo experiments using multiple doses and assessing B cells harvested from various organs demonstrated a consistent dose-dependent pattern of heightened IgM expression driven by PF-303 administration, with minor modulation of surface IgD levels (Fig. 6E) . The kinetics of IgM and IgD surface expression modulation by peripheral blood B cells were examined in a longterm pulse-chase experiment, with heightened IgM expression detectable as early as 2 d after the initiation of dosing (Supplemental Fig. 1B ). The expression levels of surface CD19, CD22, B220, and CD79b were also assessed, with a slight, yet significant, decrease in CD22 and B220 expression and an increase in the levels of CD79b (Fig. 6F) . The ability of naive B cells to express both IgM and IgD isotypes results from an alternative splice reaction of premRNA transcripts encoding the VDJ region together with both the Igh-6 and Igh-5 C region genes. As such, transcript levels derived from both the Igh-6 and Igh-5 genes were assessed. The PF-303-driven increase in IgM surface expression levels was not represented at the mRNA level, because transcripts derived from both the Igh-6 and Igh-5 genes in purified B cells from chronic PF-303-versus vehicle-treated mice were unchanged (Fig. 6G) . Because this suggests that a posttranscriptional regulatory mechanism is driving heightened IgM expression levels, we assessed the impact of chronic PF-303 treatment on IgM turnover. B cells were harvested from mice dosed with vehicle or PF-303 either 5 d prior to sacrifice (chronic treatment) or 2 h prior to sacrifice (acute treatment), as well as from xid mice. B cells from xid mice and mice chronically dosed with PF-303 exhibited decreased IgM internalization rates compared with B cells obtained from vehicle-treated mice and mice acutely treated with PF-303 (Fig. 6H) . These data indicate that chronic BTK inhibitor treatment drives the accumulation of surface IgM, in part, by decreasing the IgM protein internalization rate. (4, 13) . The temporal use of a BTK inhibitor provided an opportunity to test, in wild-type mice, whether BTK is required for the development of B1 cells or for their survival and/or function. Surprisingly, chronic treatment of mice with PF-303 revealed the sustained presence of both B1a and B1b subsets (Fig. 7A) (Fig. 7B, 7C ). Indicating PF-303 engagement of BTK, heightened IgM expression by transferred B1 cells was observed in the PF-303 cohort (Fig. 7D) . The ability of transferred B1 cells to produce phosphorylcholine-reactive Ab was equivalent in both vehicle-and PF-303-treated RAG2 2/2 groups receiving B1 cells (Fig. 7E) ; in addition, treatment of wild-type mice with PF-303 did not impact anti-PC IgM titer (Fig. 7F) . Although it is possible that the duration of chronic BTK inhibition required to impact B1 cells may exceed the 14 d time-frame assessed in these studies and that levels of PF-303 in the peritoneal cavity differ from plasma levels of PF-303, these data collectively indicate that B1 cells require BTK for their development but not persistence or function. (Fig. 8A, 8B (Fig. 8C, 8D ). Nonisotype-switched PE-specific memory B cells (defined as B220 + Dump 2 PE + CD38 + IgM + IgD + ) were depleted by BAFFR-Fc treatment (Fig. 8E) , indicating that IgM + memory B cells require BAFF for survival. Memory B cells were still functional after a course of BTKinhibitor treatment; dosing with PF-303 and/or BAFFR-Fc for 14 d, followed by a 5-d compound wash-out period, had no impact on anti-PE recall responses mounted after PE rechallenge (Fig. 8F,  8G ). We also examined the impact of long-term dosing of PF-303 on serum Ab titers. After 2 wk of dosing, a minor, dose-dependent impact was observed on polyclonal IgG2a and IgG3 titers (Fig. 9A) . Importantly, polyclonal IgG + ASC numbers in the bone marrow remained unchanged between the vehicle and PF-303 cohorts (Fig. 9B) . Mice containing an established pool of bone marrowresident ASCs elicited by priming and boosting with the Ag NP 19 -CGG were treated with either PF-303 or vehicle for 33 d, with an additional 25 d wash-out period (Fig. 9C) . Anti-NP IgG titers did not change in vehicle-or PF-303-treated cohorts for the duration of the experiment; in addition, NP-specific ASCs in the bone marrow did not differ between these two cohorts (Fig. 9D) . Collectively, these data demonstrate that chronic BTK inhibition does not impact memory B cell or bone marrow-resident ASC survival or function. (Fig. 10A) . However, upon quantification of B220 + Dump 2 CD38 + PE + BrdU + cells, a significant reduction in numbers was observed in the PF-303 group compared with vehicle controls (Fig. 10B) . In addition, a significant reduction in serum anti-PE IgG titers was observed in the PF-303-treated group in comparison with vehicle controls (Fig. 10C, 10D) . To eliminate the potentially confounding variable of the presence of serum anti-PE Abs at the time of Ag rechallenge, CD138 + -depleted splenocyte preparations from PE-primed mice were adoptively transferred into naive wildtype mice, with recipient mice administered either PF-303 or vehicle, followed by PE rechallenge. Notably, PF-303 completely suppressed both the PE-specific IgM and IgG Ab response in comparison with corresponding controls (Fig. 10E,  10F) . These data collectively demonstrate that BTK inhibition by PF-303 suppresses the memory B cell-derived ASC burst in response to cognate Ag.
Discussion
These experiments model how pharmacological BTK inhibition, as opposed to genetic inactivation of the btk gene, will impact humoral immune parameters and mature immune responses in a clinical setting. Our results predict that modulation of tonic signaling, depletion of immature and anergic T3-like B cells, and an increase in IgM surface expression and serum BAFF levels will occur in the clinic. In addition, fine mapping of the types of B cell responses modulated by BTK inhibition clarifies the immune competence of treated patients by suggesting that both innate and adaptive Ig titers will not be impacted, and it suggests the potential usefulness of BTK inhibition in the treatment of both oncologic and autoimmune etiologies driven by GC and memory B cell subsets.
Our assessment of how BTK inhibition modulates the naive B cell transcriptome identified BTK-dependent and -independent transcripts downstream of the BCR. Although the majority of antiIgD-modulated transcripts were BTK dependent, BTK inhibition had an incomplete effect in returning perturbed transcripts to baseline levels. In addition, a number of anti-IgD-dependent, BTK-independent transcripts were identified; these microarray studies demonstrate that BTK inhibition does not shut down BCR signaling entirely. Importantly, these experiments implicated BTK function in tonic BCR signaling, with tonic signals demonstrated to be necessary for B cell survival (41) (42) (43) . Interestingly, we did not see similar degrees of B cell depletion observed with PF-303 treatment as was achieved with genetic deletion of BCR components or SYK (41, 43, 44) ; this may be due to the presence of the BCR-dependent, BTK-independent pathways unveiled in our microarray experiments.
While investigating the impact of chronic BTK inhibition on B cell subset homeostasis, we demonstrated increased serum BAFF levels and depletion of B cells in the secondary lymphoid organs but not the peripheral blood. The increase in serum BAFF levels is expected, given the established inverse correlation of BAFF levels with peripheral B cell frequencies. The differential B cell depletion in the peripheral blood versus the secondary lymphoid organs may be the consequence of the established role for BTK in mediating B cell homing to the chemokine CXCL13 (45) . Interestingly, ibrutinib was reported to induce the purging of malignant cells from the lymphoid tissues into the peripheral blood (46) . Importantly, these data indicate that assessment of B cell frequencies in the peripheral blood of BTK inhibitor-treated patients may not reflect the extent of B cell depletion within the secondary lymphoid organs. We also observed that BTK inhibition imparts a developmental block and prevents replenishment of the T3 B cell subset. Prior studies in xid mice observed a defect in the T3 B cell subset (39) . Importantly, this population is enriched for anergized B cells (47) These studies provide a predictive overview of how a patient undergoing BTK inhibition may respond to various antigenic insults. The impact of PF-303 on primary Ab responses largely mimics the described xid phenotype, with BTK inhibition inhibiting T-independent type II, but not type I, responses and incompletely modulating T-dependent Ab responses. Importantly, for indications in which GC structures have been implicated in disease etiology, such as primary Sjögren's syndrome or SLE, we demonstrate that BTK inhibition prevents the onset and continuation of established GC B cell responses, including in Peyer's patches. Our in vitro studies implicate a role for PF-303 in driving impaired B cell-driven cognate CD4 T cell activation, a novel mechanism that may contribute to the prevention and dissolution of GC responses in vivo. In our studies, we demonstrate that, although memory B cells enter the cell cycle in response to secondary Ag encounter, PF-303 significantly suppressed memory B cell clonal expansion and the ASC burst. Given the relapsing and remitting nature of autoimmunity and the association of peripheral CD27 + memory B cells in both SLE and rheumatoid arthritis, perturbation of memory B cells by BTK inhibition is desirable. Interestingly, these results diverge from published data, obtained using xid mice, showing that memory B cell reactivation and the resulting ASC response are independent of BTK activity (27) . This discordance may be a consequence of these studies being performed in a wild-type setting and without the potentially compensatory mechanisms at play in the xid strain or from the PF-303 compound engaging TEC and BMX to a similar degree as BTK. Indeed, functional redundancy between BTK and TEC downstream of the BCR was reported in the murine system (48) .
Because of the protective nature of serum Ab titers and their essential function in combating infection, we assessed how chronic BTK inhibition impacted B1 B cells, bone marrow-resident ASCs, and memory B cell survival. We conclude that the persistence of these subsets is independent of BTK function. We also tested whether dual inhibition of BTK and BAFF impacted memory B cell survival. The signals driving memory B cell survival remain obscure given the independence of this population from BAFF survival signals (49, 50) . We hypothesized that concomitant BTK and BAFF blockade might uncover a redundancy between BAFFR and the BCR in their ability to transmit survival signals. We observed that BTK inhibition in the presence of BAFF antagonism did not impact IgG + memory B cell survival, but it did deplete IgM + memory B cells. To summarize, these data predict the clinical course of BTK inhibition and help to clarify its clinical utility, both in the context of oncology settings, in which BTK inhibition is already used, and in the context of autoimmune diseases, in which the next generation of BTK inhibitors likely will be of use. 
